Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial
- PMID: 24710342
- DOI: 10.1093/tropej/fmu022
Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial
Abstract
Background: Corticosteroids have been evaluated for management of severe Mycoplasma pneumoniae pneumonia (MP) in children. However, it is unclear whether the timing of treatment with corticosteroids affects the patients' clinical outcome.
Methods: We did a prospective randomized clinical trial to evaluate the effect of early use of corticosteroids. Fifty-three patients were randomly assigned to treatment with corticosteroids within 24 h after admission (cases), and 53 patients were treated 72 h after admission (control patients).
Results: Cases had a shorter fever duration [6 days (range 5-11) vs. 10 days (range 8-23), p < 0.001] and length of hospital stay [8 days (range 5-15) vs. 10 days (range 5-21), p = 0.001]. Four cases (1.9%) had a complete radiographic resolution time >4 weeks compared with 10 control patients (17.5%; p = 0.038; Table 2).
Conclusions: Early treatment with corticosteroids was associated with a better outcome in patients with severe MP.
Keywords: Mycoplasma pneumoniae pneumonia; corticosteroids.
© The Author [2014]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
[The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].Zhonghua Jie He He Hu Xi Za Zhi. 2013 Oct;36(10):756-61. Zhonghua Jie He He Hu Xi Za Zhi. 2013. PMID: 24433804 Chinese.
-
Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children.Pediatr Pulmonol. 2006 Mar;41(3):263-8. doi: 10.1002/ppul.20374. Pediatr Pulmonol. 2006. PMID: 16437541
-
Prediction of risk factors of bronchial mucus plugs in children with Mycoplasma pneumoniae pneumonia.BMC Infect Dis. 2021 Jan 13;21(1):67. doi: 10.1186/s12879-021-05765-w. BMC Infect Dis. 2021. PMID: 33441105 Free PMC article.
-
[Mycoplasma pneumoniae pneumopathy. 10 cases].Presse Med. 1999 Jan 16;28(2):59-66. Presse Med. 1999. PMID: 9989294 Review. French.
-
Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature.J Infect Chemother. 2014 Mar;20(3):181-5. doi: 10.1016/j.jiac.2013.09.009. Epub 2013 Dec 11. J Infect Chemother. 2014. PMID: 24462437 Review.
Cited by
-
Clinical efficacy of macrolide antibiotics in mycoplasma pneumoniae pneumonia carrying a macrolide-resistant mutation in the 23 S rRNA gene in pediatric patients.BMC Infect Dis. 2024 Jul 31;24(1):758. doi: 10.1186/s12879-024-09612-6. BMC Infect Dis. 2024. PMID: 39085799 Free PMC article.
-
Corticosteroids for pneumonia.Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD007720. doi: 10.1002/14651858.CD007720.pub3. Cochrane Database Syst Rev. 2017. PMID: 29236286 Free PMC article.
-
Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management.J Clin Med. 2022 May 17;11(10):2824. doi: 10.3390/jcm11102824. J Clin Med. 2022. PMID: 35628949 Free PMC article. Review.
-
Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.Korean J Pediatr. 2017 Jun;60(6):167-174. doi: 10.3345/kjp.2017.60.6.167. Epub 2017 Jun 22. Korean J Pediatr. 2017. PMID: 28690643 Free PMC article. Review.
-
Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia.BMC Pulm Med. 2017 Dec 29;17(1):219. doi: 10.1186/s12890-017-0566-4. BMC Pulm Med. 2017. PMID: 29284447 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical